Prescription patterns in an intensive care unit of COVID‐19 patients in Bangladesh: A cross‐sectional study

Rahman, Tanvir; Islam, Md. Saiful; Paul, Shyamjit; Islam, Md. Momin; Samadd, Md. Abdus; Reyda, Rashmia Nargis; Sarkar, Md. Raihan

doi:10.1002/hsr2.1711

Cited by 1 publication

(2 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, anticoagulant prescriptions on the wards seemed lower than reported in other investigations [13,15]. For instance, a study on COVID-19 in critically ill inpatients from Spain demonstrated that 89.1% received LMWH at hospital admission [15,17].…”

Section: Discussionmentioning

confidence: 78%

“…In 2021, a retrospective study conducted in Spain reported that 85% of critically ill patients received a prescription for anticoagulant therapy with enoxaparin as the most prescribed medication [12]. Similarly, a recent investigation reported that anticoagulants accounted for most of the prescriptions performed in suspected and confirmed COVID-19 patients admitted to an ICU [13].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Antithrombotic Use Patterns in COVID-19 Patients from Spain: A Real-World Data Study

Ramirez-Cervantes,

Campillo-Morales,

García-Poza

et al. 2024

JCM

View full text Add to dashboard Cite

Antithrombotics have been widely used to treat and prevent COVID-19-related thrombosis; however, studies on their use at population levels are limited. We aimed to describe antithrombotic use patterns during the pandemic in Spanish primary care and hospital-admitted patients with COVID-19. Methods: A real-world data study was performed. Data were obtained from BIFAP’s electronic health records. We investigated the antithrombotic prescriptions made within ±14 days after diagnosis between March 2020 and February 2022, divided their use into prior and new/naive groups, and reported their post-discharge use. Results: We included 882,540 individuals (53.4% women), of whom 78,499 were hospitalized. The median age was 44.7 (IQR 39–59). Antithrombotics were prescribed in 37,183 (4.6%) primary care subjects and 42,041 (53.6%) hospital-admitted patients, of whom 7505 (20.2%) and 20,300 (48.3%), respectively, were naive users. Prior users were older and had more comorbidities than new users. Enoxaparin was the most prescribed antithrombotic in hospitals, with higher prescription rates in new than prior users (2348.2, IQR 2390–3123.1 vs. 1378, IQR 1162–1751.6 prescriptions per 10,000 cases, p = 0.002). In primary care, acetylsalicylic acid was the most used antithrombotic, with higher use rates in prior than in naïve users. Post-discharge use occurred in 6686 (15.9%) subjects (median use = 10 days, IQR 9-30). Conclusions: Our study identified a consensus on prescribing antithrombotics in COVID-19 patients, but with low use rates in hospitals.

show abstract